Impact of Lenalidomide in Management of FL and MZL
Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief of the Division of Lymphomas discusses how the approval of lenalidomide ...
Author: obr
Added: 06/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2019 Category: Cancer & Oncology Source Type: podcasts
Trial Updates At ASCO: Approval Of Daratumumab In Combination With Revlimid Or Velcade & Dexamethasone
Robert Rifkin MD Of US Oncology Research Discusses Trial Updates At ASCO: Approval Of Daratumumab In Combination With Revlimid Or Velcade & Dexamethasone.
Author: Annual-Meeting
Added: 06/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2019 Category: Cancer & Oncology Source Type: podcasts
MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed By Maintenance Therapy In Relapsed/Refractory NHL.
David Andorsky MD Of US Oncology Research Discusses MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed By Maintenance Therapy In Relapsed/Refractory NHL.
Author: Annual-Meeting
Added: 06/03/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 3, 2019 Category: Cancer & Oncology Source Type: podcasts
Lenalidomide + Azacitidine Graft v Host
Dr. Charles Craddock, MD discusses Graft V Host disease when combining Lenalidomide + Azacitidine
Author: Annual-Meeting
Added: 05/31/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 31, 2019 Category: Cancer & Oncology Source Type: podcasts
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
Charles Craddock MD PhD @charliecraddock of Queen Elizabeth Hospital discusses the Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell ...
Author: Annual-Meeting
Added: 05/31/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 31, 2019 Category: Cancer & Oncology Source Type: podcasts
Addition Of Daratumumab To Revlimid/Dexamethasone In MM
Maria-Victoria Mateos, MD Associate Professor of Medicine, University of Salamanca, discusses Addition Of Daratumumab To Revlimid/Dexamethasone In MM. At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: obr
Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts
Lenalidomide In High Risk MDS Patients
Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses Lenalidomide In High Risk MDS Patients at Lymphoma & Myeloma on October 18, 2018.
Author: imedex
Added: 12/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 31, 2018 Category: Cancer & Oncology Source Type: podcasts
ISA Combo: Velcade, Revlimid & Dexamethasone
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses ISA Combo: Velcade, Revlimid & Dexamethasone At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: ASHReport
Added: 12/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 18, 2018 Category: Cancer & Oncology Source Type: podcasts
OPTIMISMM: benefits of a new triplet therapy for MM patients relapsing on lenalidomide
Meletios Dimopoulos, MD, of the University of Athens School of Medicine, Athens, Greece, gives an overview of the OPTIMISMM trial (NCT01734928) at the 2018 Society of Hematologic Oncology (SOHO) Annua...
Author: VJHemOnc
Added: 09/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 19, 2018 Category: Cancer & Oncology Source Type: podcasts
OPTIMISMM: investigating an alternative therapy for lenalidomide-refractory patients
Lenalidomide is widely used for multiple myeloma (MM); however, while it is effective, most patients relapse and become lenalidomide-refractory. In this interview, conducted at the 23rd Congress of th...
Author: VJHemOnc
Added: 08/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Results of RELEVANCE: frontline rituximab-lenalidomide for follicular lymphoma
Results of the Phase III RELEVANCE trial (NCT01476787) of rituximab-lenalidomide for untreated follicular lymphoma were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chic...
Author: VJHemOnc
Added: 07/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 30, 2018 Category: Cancer & Oncology Source Type: podcasts
FORTE update: carfilzomib-lenalidomide induction therapy for MM
Francesca Gay, MD, of the University of Torino, Torino, Italy, provides an efficacy data update from the FORTE trial (NCT02203643), which investigated carfilzomib plus lenalidomide or cyclophosphamide...
Author: VJHemOnc
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
MMY1001 subgroup: daratumumab-Kd in lenalidomide refractory MM
While there are many clinical trials exploring the effect of various novel agents in combination with lenalidomide-dexamethasone therapy in multiple myeloma (MM), patients who are lenalidomide refract...
Author: VJHemOnc
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Thoughts on combination carfilzomib & daratumumab in revlimid-refractory multiple myeloma
Noa Biran, MD, discusses her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients at the 2018 Annual Meeting.
Author: obr
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Combination carfilzomib & daratumumab in revlimid-refractory multiple myeloma
Noa Biran, MD, talks about her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients at the 2018 Annual Meeting.
Author: obr
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts